Last reviewed · How we verify
BDP/salbutamol CFC pMDI
BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.
BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction.
At a glance
| Generic name | BDP/salbutamol CFC pMDI |
|---|---|
| Also known as | Clenil® Compositum 250 |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/short-acting beta-2 agonist combination (ICS/SABA) |
| Target | Glucocorticoid receptor (BDP); beta-2 adrenergic receptor (salbutamol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate (BDP) is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors, reducing mucus production and airway edema. Salbutamol (albuterol) is a short-acting beta-2 adrenergic agonist that rapidly relaxes bronchial smooth muscle, providing acute bronchodilation. The CFC formulation uses chlorofluorocarbon propellants in a pressurized metered-dose inhaler (pMDI) for drug delivery.
Approved indications
- Asthma maintenance and reliever therapy
- Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Throat irritation
- Nervousness/anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP/salbutamol CFC pMDI CI brief — competitive landscape report
- BDP/salbutamol CFC pMDI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI